Skip to main content

Table 3 Segmented regression analysis on the monthly ACEIs prescription proportion in the 13 UK regions

From: The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design

Regions β1(a) β2(b) β3(c) β4(d) β5(e) β6(f) β7(g)
High baseline ACEIs prescription proportion (>74 %)
  North East −0.12 (−0.13, −0.11) --- --- --- 0.04 (0.02, 0.06) --- ---
  South East −0.06 (−0.70, −0.05) −0.31 (−0.7, −0.07) 0.02 (0.01, 0.04) --- --- --- ---
  Wales --- --- --- --- --- --- ---
  East Midlands −0.03 (−0.04, −0.16) --- --- −0.64 (−1.1, −0.20) 0.16 (0.13, 0.19) --- ---
Intermediate baseline ACEIs prescription proportion (65 %-74 %)
  Yorkshire and the Humber −0.08 (−0.09, −0.06) --- 0.20 (0.14, 0.24) −1.80 (−0.26,-0.9) --- --- ---
  East of England −0.08 (−0.70, −0.05) −0.40 (−0.7, −0.05) 0.02 (0.04, 0.03) --- --- --- ---
  South Central −0.01 (−0.2, −0.002) −0.60 (−0.9, −0.40) --- −0.47 (−0.7, −0.20) --- --- ---
  Scotland --- --- 0.06 (0.04, 0.08) −0.49 (−0.80, −0.10) --- --- ---
  West Midlands --- --- −0.03 (−0.04, −0.02) --- --- --- ---
  North West 0.01 (0.02, 0.018) −0.57 (−0.8, −0.33) 0.04 (0.03, 0.05) --- --- --- ---
  London --- 0.40 (0.20, 0.60) --- --- 0.04 (0.03, 0.05) --- ---
Low baseline ACEIs prescription proportion (<65 %)
  South East Coast 0.013 (0.004, 0.02) −0.42 (−0.7, −0.20) −0.02 (−0.03,-0.002) --- --- --- ---
  Northern Ireland 0.06 (0.05, 0.08) --- --- --- 0.06 (0.02, 0.09) --- ---
  1. Regression coefficients (95 % confidence intervals) for the final model (the most parsimonious models); (a)baseline trend; (b)level change following BCBV policy; (c)trend change following BCBV policy; (d)level change following generic losartan availability; (e)trend change following generic losartan availability; (f)level change following generic perindopril availability; (g)trend change following generic perindopril availability; −--: indicates insignificant estimates at 0.05 level, after stepwise backward elimination; ACEIs: Angiotensin converting enzyme inhibitors